Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Mustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

May 10, 2019

Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

May 10, 2019

Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

May 09, 2019

Mustang Bio Announces Full Exercise of Option

May 08, 2019

Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

May 08, 2019

Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

May 01, 2019

Mustang Bio Announces Pricing of Public Offering of Common Stock

Apr 30, 2019

Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors

Apr 30, 2019

Mustang Bio Announces Proposed Public Offering of Common Stock

Apr 29, 2019

St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine

Apr 17, 2019
RSS
  • Prev
    • 1...
    • 47
    • 48
    • 49
    • 50
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap